Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

3.290 +0.020 (+0.61%)

Streaming Delayed Price Updated: 12:14 PM EDT, Sep 10, 2026 Add to My Watchlist

Price and Volume

Volume	88,628
Open	3.540
Bid (Size)	3.280 (600)
Ask (Size)	3.300 (100)
Prev. Close	3.270
Today's Range	3.200 - 3.552
52wk Range	1.300 - 4.850
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Today 8:00 EDT

From Adagene Inc.

Via GlobeNewswire

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

September 09, 2026

From Adagene Inc.

Via GlobeNewswire

Performance

YTD	+78.8%	+78.8%
1 Month	-19.2%	-19.2%
3 Month	-0.9%	-0.9%
6 Month	-7.3%	-7.3%
1 Year	+31.6%	+31.6%

More News

Adagene to Participate in Three Upcoming Investor Conferences

August 20, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

August 12, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer ↗

May 19, 2026

Via MarketBeat

Adagene to Participate in Two Upcoming Investor Conferences

May 12, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

April 17, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

April 14, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

April 02, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

April 02, 2026

From Adagene Inc.

Via GlobeNewswire

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

April 02, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

April 01, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

March 17, 2026

From Adagene Inc.

Via GlobeNewswire

Top movers in Wednesday's session ↗

March 11, 2026

Via Chartmill

Adagene to Participate in Two Upcoming Investor Conferences

February 17, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Provides Business Update and 2026 Objectives

January 23, 2026

From Adagene Inc.

Via GlobeNewswire

These stocks are gapping in today's session ↗

December 16, 2025

Via Chartmill

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

December 16, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

November 13, 2025

From Adagene Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 11, 2025

Via Benzinga

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

October 31, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

September 16, 2025

From Adagene Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 09, 2025

Via Benzinga

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

September 05, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

September 03, 2025

From Adagene Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?

Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.

What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?

Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market

What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?

The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market

What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?

The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 3.290

When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?

The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 09/10/26 12:14 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.